Cambridge Cognition announces first NeuroVocalix commercial partnership

19th Sep 2018 10:14

(Sharecast News) - Neuroscience technology company Cambridge Cognition Holdings announced its first commercial partnership for its recently launched 'NeuroVocalix' voice biomarker technology on Wednesday.The AIM-traded firm said NeuroVocalix enabled the remote assessment of voice-based cognitive measures.In the first contract, the technology would be licensed for use in an "innovative" virtual clinical trial with a global pharmaceutical company.The four week study would include two verbal NeuroVocalix cognitive tests delivered alongside Cambridge Cognition's CANTAB and Cognition Kit assessments, all administered directly to study participants on their smartphones.It said the collection of objective and frequent cognitive data made possible by the company's near-patient digital health technologies enabled pharmaceutical sponsors to identify efficiencies in both time and cost.Traditional methods of clinical trials, which used multiple study sites and required multiple patient visits to sites, had high attrition rates with as many as 40% of Phase III trial participants dropping out, the company explained.Virtual clinical trials represented a relatively new method of collecting safety and efficacy data, using digital technologies to conduct clinical trials from patients' homes to keep participants engaged with the study, leading to better data quality and shorter timelines, it added.With the company's NeuroVocalix, CANTAB Recruit and Cognition Kit products all being delivered to patients' own devices, Cambridge Cognition said sponsors could now administer cognitive outcome assessments virtually at all stages of a clinical trial, from recruitment to post-marketing."We are pleased to confirm this first contract for use of the novel voice platform in an industry sponsored clinical trial so soon after its launch," said Cambridge Cognition chief executive officer Dr Steven Powell."This demonstrates our continued commitment to innovative R&D projects, which will benefit our pharmaceutical clients and shows our ability to commercialise new neuroscience technology products rapidly."